- Home
- UGRO vs GTBP Comparison
UGRO vs GTBP Comparison
Compare UGRO & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UGRO | GTBP |
|---|---|---|
| Founded | 2014 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UGRO | GTBP |
|---|---|---|
| Price | $0.31 | $0.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 1.6M |
| Earning Date | 03-27-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $59,985,138.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $28.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.21 | $0.54 |
| 52 Week High | $1.26 | $4.10 |
Technical Indicators
Market Signals| Indicator | UGRO | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 47.17 |
| Support Level | $0.23 | $0.58 |
| Resistance Level | $0.25 | $0.82 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 49.57 | 32.15 |
Price Performance
Historical ComparisonAbout UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.